Once again in 2015, the ADA and the EASD have opportunely pointed the need of a patient-centered approach for the management of hyperglycemia in individuals with type 2 diabetes (T2DM) [1] . A HbA 1c cut off \7 % has been suggested with more or less stringent targets to be individually pursued according to patient/disease features (PDFs), including: (a) risks associated with hypoglycemia; (b) disease duration; (c) life expectancy; (d) comorbidities; (e) vascular complications; and (f) patient's attitude. Since the ADA/EASD made clear that scale for such approach ''is not designed to be applied rigidly but to be used as a broad construct to guide clinical decision making,'' many clinicians will appreciate to be told how to measure the above-mentioned PDFs. We addressed this issue by firstly proposing a way to score individual PDFs and then investigating the distribution of such scores in a real-life clinical set. Data from 400 consecutive out-patients with T2DM attending two research-based hospitals in Central-Southern Italy, ''Casa Sollievo della Sofferenza,'' Scientific Institute in San Giovanni Rotondo (SGR, n = 200) and ''Sapienza'' University Policlinico Umberto I Hospital in Rome (Rome, n = 200) were collected.
Each of the six ADA/EASD suggested PDF was scored equal to 0 (good), 1 (intermediate) or 2 (poor). Scoring criteria (Table 1) were pre-specified in a collaborative fashion by all authors and then used independently by four authors who are experienced diabetologists (i.e., taking care of [20 patients/week since 10-35 years; AP, SDC in SGR; MF, SM in Rome). Within each hospital, concordance between scores attributed to each single PDF in each patient was observed in more than 95 % cases. In the absence of agreement, the final score was attributed upon confrontation between the two examiners. Mean values attributed to each single PDF were summed to obtain the total individual PDFs score.
Patients' clinical features are summarized in Table 2 . Median value of individual PDFs score was 6, with only one patient scoring 0 and no patients scoring 11 or 12. Patients were then grouped according to score 0-2, (n = 41, 10.2 %), 3-4 (n = 85, 21.2 %), 5-6 (n = 136, 34.0 %), 7-8 (n = 111, 27.8 %) and 9-10 (n = 27, 6.8 %), arbitrarily defined as ''very good,'' ''good,'' ''intermediate,'' ''poor'' and ''very poor,'' respectively.
According to ADA/EASD patient-centered approach, which patients should be targeted to an intensive anti-diabetes therapy (HbA 1c \ 7 %)? Probably, only those with ''very good'' or ''good'' PDFs scores? If so, more than twothirds of our patients should be targeted to more relaxed attempts (HbA 1c \ 7.5 % or more). In fact, the majority of study patients had a score ranging from ''intermediate'' to ''very poor,'' while only 31.4 % show a ''very good'' or ''good'' score. A similar conclusion could have been drawn according to a totally independent ADA suggestion, specifically devoted to elderly people ([65 years). In this subgroup, the ADA recommends a level of HbA 1c \ 7.5 % rather than 7 % if patients are otherwise healthy with intact cognitive and functional status, more relaxed targets are indicated for elderly with comorbidities (HbA 1c \ 8.0 % or even \8.5 %) [2] . Of note, 255 (63.7 %) of our study patients were in fact C65 years old, a finding which is similar to that reported in larger epidemiological surveys, and thus candidates, by the only virtue of age, to a relaxed HbA 1c target (\7.5 % or more). Such a proportion is similar to that obtained by using the PDFs score (68.6 % of our patients scored as ''intermediate,'' ''poor'' or ''very poor'' score), thus somehow validating the results obtained by PDFs score and reinforcing the idea that, in our clinical set, intensive anti-diabetes therapy is suggestible for a minority of patients. Are our findings interpretable in the context of metaanalyses of trials addressing the impact of intensive glucose lowering therapy on all-cause mortality which showed, quite unexpectedly, no benefit at all? Probably yes; in fact, among possible explanations of such counterintuitive negative result is certainly-on one side-the deleterious role of severe hypoglycemia [3, 4] , which is ineludibly associated with intensive anti-diabetes therapy, but-on the other side-also the possibility that intensive treatment should be limited to younger patients, with short disease duration and lack of major chronic complications and comorbidities, all patients whose PDFs score would conceivably be defined as ''very good'' or ''good'' by our scoring method.
Although we recognize that our scoring method does not derive from objective standardized measurements (especially the one referring to patient's attitude, which is only based on personal judgment of experienced diabetologists), it is of note that more than 95 % agreement was observed between the two examiners within the each hospital, thus internally validating it. A further limitation of our scoring method, which is based on the arbitrary assumption of an equivalent role played by each PDF, is that the contribution of each feature is not ''weighted'' according to its own importance in determining the level of treatment intensiveness. This might end up to different individual HbA 1c targeting. For example, it is conceivable, and probably agreeable, that individuals with previous major cardiovascular events, even in the absence of other counter-indications (thus scoring only 2), should be preferentially targeted to a relaxed glycemic control. It is worth noting that, under this scenario (or similar ones), our scoring method, if any, underestimates the proportion of patients targetable to more relaxed HbA 1c levels. In all, though some suggestions from experienced people have been recently offered [5] , specifically designed prospective studies aimed at objectively addressing the individual weight to be attributable to each PDF are definitively needed.
In conclusion, despite the above-mentioned limitations, we believe our present report has the merit of proposing a method for measuring ADA/EASD suggested PDFs to eventually be used for pursuing a patient-centered glucose lowering treatment. According to the proposed method, in the real-life clinical set of Central-Southern Italy, the majority of patient attending diabetes clinics from research-based hospitals seems not to be eligible to intensive anti-diabetes treatments. Additional attempts are needed to address the generalizability of our finding and to better shape the specific weight of each single PDF in determining the degree of intensiveness of anti-diabetes treatments.
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